Evidence map›Paper›PMID 31763196›Full record

ArticleBiotechnology reports (Amsterdam, Netherlands)2019

RNA silencing of

H A Walsh, H Vanderschuren, S Taylor, M E C Rey

Open access · goldAbstract read
In one paragraph

Article in Biotechnology reports (Amsterdam, Netherlands), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.7field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

H A WalshSchool of Molecular and Cell Biology, University of the Witwatersrand, 1 Jan Smuts Ave, Johannesburg, South Africa.
H VanderschurenPlant Genetics Laboratory, TERRA Teaching and Research Unit, University of Liège, Gembloux Agro-Bio Tech, Belgium.
S TaylorSchool of Molecular and Cell Biology, University of the Witwatersrand, 1 Jan Smuts Ave, Johannesburg, South Africa.
M E C ReySchool of Molecular and Cell Biology, University of the Witwatersrand, 1 Jan Smuts Ave, Johannesburg, South Africa.
University of the Witwatersrand · ZAGembloux Agro-Bio Tech · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cassava mosaic disease (CMD), caused by geminiviruses, is a major hurdle to cassava production. Due to the heterozygous nature of cassava, breeding for virus resistance is difficult, but cassava has been shown to be a good candidate for genetic engineering using RNA interference (RNAi). T This study reports on the ability of a transgene-derived RNA hairpin, homologous to an overlapping region of the SACMV replication associated protein and putative virus suppressor of silencing protein (AC1/AC4), to confer tolerance in the CMD-susceptible model cassava cultivar 60444. Three of the fourteen transgenic lines expressing SACMV AC1/AC4 hairpin-derived siRNAs showed decreased symptoms and viral loads compared to untransformed control plants. Expression of SACMV AC1/AC4 homologous siRNAs showed that this tolerance is most likely associated with post-transcriptional gene silencing of the virus. This is the first report of targeting the overlapping AC1 and AC4 genes of SACMV conferring CMD tolerance in cassava.

Indexed as

AC1, replication associated proteinAC4, Silencing suppressor proteinCassavaCMD, Cassava mosaic diseasehp-RNA, hairpin RNAPost-transcriptional gene silencingRecoverySACMV, South African cassava mosaic virussiRNA, Small interfering RNASouth African cassava mosaic virusToleranceVSR, virus suppressor of RNA silencing

Identifiers

PMID31763196
PMCPMC6864324
OpenAlexW2987940737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.